Triple-negative breast cancer research hub
37 indexed studies · 21 currently recruiting
- completedNot Applicable
LOTUS: LOng-Term follow-Up Study of triple-negative breast cancer
The LOTUS study is looking at the long-term health of people with triple-negative breast cancer who previously took part in a trial called BEATRICE. Researchers want to understand how past treatments affect health over many years, helping doctors improve care and support for future patients.
United Kingdom · England · Australia - authorisedTherapeutic exploratory (Phase II)
DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer
This trial looks at early triple-negative breast cancer. Researchers want to find out if 12 weeks of combined chemotherapy and immunotherapy before surgery can completely clear the tumour. If successful, this shorter treatment could help patients avoid heavier chemotherapy drugs, reducing difficult side effects while keeping care effective.
France - authorisedPhase II and Phase III (Integrated)
Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified to radical therapy
This study tests a new imaging scan called PSMA-T4 in women with triple-negative breast cancer. Doctors want to see if this scan can highlight cancer cells clearly before surgery. The goal is to find out if it helps predict how the cancer behaves and guide better future care.
Poland - recruitingTherapeutic confirmatory (Phase III)
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290)
This study is looking at a new combination of treatments for advanced triple-negative breast cancer. It compares a drug called capivasertib with paclitaxel, to paclitaxel alone, to see if the new combination improves survival and is safe.
Spain - recruitingTherapeutic confirmatory (Phase III)
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer
The GLORIA study is looking at a new vaccine, Adagloxad Simolenin, for people with a type of breast cancer called triple-negative breast cancer that has a specific marker called Globo H. It aims to see if this vaccine, given after initial treatment, can help prevent the cancer from coming back.
Poland - active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study is for people with a specific type of advanced breast cancer (PD-L1 positive triple-negative) that hasn't been treated yet. It compares two different drug combinations to see which one works better at stopping the cancer from growing.
United States · Argentina · Australia - active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study looks at a new drug, Sacituzumab Govitecan-hziy, for people with an aggressive type of breast cancer called triple-negative breast cancer that has spread or can't be operated on. It compares this new drug to standard treatments to see which works better at stopping the cancer from growing.
United States · Argentina · Australia - recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
France - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - authorisedTherapeutic confirmatory (Phase III)
PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy – the multicenter, randomized phase III, pragmatic PLANET trial
This study looks at new treatments for early-stage triple-negative breast cancer that hasn't completely gone away after initial treatment. It compares different medicines to see if they can stop the cancer from coming back, helping people live longer and healthier lives.
Netherlands - recruitingPHASE3
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
This study is testing a new drug, sacituzumab govitecan, for people with an advanced type of breast cancer called triple-negative breast cancer. It's for those whose cancer has continued to grow after other treatments. The aim is to see how well it works and understand who it helps most.
France - recruitingPHASE2
Triple Negative Breast Cancer and Celecoxib. Pilot Study
This study is looking at whether a drug called celecoxib can help prevent breast cancer from coming back in women with triple-negative breast cancer. It's a small first study to see if a larger study is possible and if the drug affects certain body signals during radiotherapy.
Canada - active not recruitingPHASE1
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
This study looks at combining two drugs, palbociclib and avelumab, for a specific type of advanced breast cancer called triple negative. We want to find the safest dose and see how well it works, especially for cancers with a particular marker called AR.
United Kingdom - not yet recruitingNA
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
This study looks at how high-intensity exercise might help women with a specific type of breast cancer (triple-negative breast cancer) when they're having cancer treatment. Researchers want to see if this exercise can improve how well treatments work and help the body fight the cancer better.
Germany - recruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
This study is looking at new treatments for triple-negative breast cancer that remains after surgery. It compares a new drug combination (sacituzumab govitecan-hziy and pembrolizumab) with standard treatments to see if it's more effective and safe for patients.
United States · Australia · Belgium - recruitingNA
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
The CUPCAKE study looks for early signs of breast cancer recurrence in women who previously had triple-negative breast cancer. It uses special blood tests and scans to find if the cancer has returned earlier than usual to see if earlier detection helps.
France - recruitingPHASE1
A Study of LY4175408 in Participants With Advanced Cancer
This study is looking at a new medicine called LY4175408 for people with certain advanced cancers, including lung, womb, and a type of breast cancer. It aims to see if the medicine is safe, how well it works, and how the body handles it.
United States · China · France - active not recruitingPHASE1
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
This study is testing a new combination of two drugs, ASTX660 and pembrolizumab, for people with advanced cancers like cervical cancer and a type of breast cancer. It's a first step to see if this new approach can boost the body's own immune system to fight cancer.
United Kingdom - recruitingPHASE1
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
This study in Canada tests a new treatment, GCAR1, for specific advanced cancers like certain breast, kidney, and bone cancers. Researchers want to find the safest dose and see if it helps slow down cancer by using the body's own immune cells.
Canada - active not recruiting
Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients
This study, called PERCEPTION, is for women with triple negative breast cancer. It looks at how blood cell counts and special immune cells in tumours are linked, both before and after surgery. It also explores if these can predict if the cancer might come back.
France - not yet recruitingPHASE3
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
This study looks at new ways to treat a type of breast cancer called triple-negative early breast cancer. It compares a new drug combination with standard treatment to see if it works better at shrinking tumours before surgery and stopping cancer from coming back.
Germany - recruiting
Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
This study aims to understand how breast cancer changes over time, especially when it spreads. Researchers will take several small tissue samples and blood tests from different areas to see how the cancer evolves. This could help develop better treatments in the future.
United Kingdom - recruiting
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
This study, called BELIEVE, collects tissue and blood samples from people with breast cancer before surgery. Researchers want to understand why some cancers respond well to treatment and others don't, how to better measure treatment success, and predict if cancer might return. It helps improve future breast cancer care.
United Kingdom - recruitingPHASE2
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
This study looks at treating early-stage triple-negative breast cancer. It explores whether less chemotherapy is needed for some patients, especially those with many immune cells (TILs) in their tumour. Some patients might receive fewer treatments than usual.
France · Spain - recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
United States · Argentina · Australia - active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This study is testing a new drug, BT5528, for advanced cancers like ovarian, lung, and breast cancer. We want to find a safe dose, understand side effects, and see how well it works, sometimes given with another drug called nivolumab.
United States · Belgium · South Korea - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - recruitingPHASE1, PHASE2
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
This study is testing a new vaccine called Modi-1 Moditope for advanced cancers like breast, head and neck, ovarian, or kidney cancer. It aims to see if it's safe, and if it can help the body fight cancer, alone or with other treatments.
United Kingdom - active not recruitingPHASE2
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
This study is testing a new drug, BNT327, for advanced breast cancer (called triple-negative). Researchers want to see if it's safe and works well when given with chemotherapy. It's for people whose cancer has spread or is difficult to treat.
United States · Australia · Turkey (Türkiye) - recruitingPHASE1
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
This study is testing a new medicine called MOv18 IgE for women with advanced ovarian, endometrial, or triple-negative breast cancer. It aims to find a safe dose and see how well it works, especially in cancers that have a specific marker called Folate Receptor Alpha.
United Kingdom - authorisedTherapeutic exploratory (Phase II)
BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
This study looks at new treatments for a specific type of breast cancer called triple-negative. It combines standard chemotherapy and Tecentriq with a new drug, Ipatasertib, to see if this combination helps shrink tumours more effectively before surgery.
Spain · Germany - recruitingPHASE2
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
This study is testing if a new combination of two drugs, Datopotamab Deruxtecan and Durvalumab, works better than Datopotamab Deruxtecan alone for a specific type of advanced triple-negative breast cancer. It focuses on patients whose cancer doesn't have a marker called PDL1.
United Kingdom - recruiting
Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)
This study is testing a new tool for people with advanced triple-negative breast cancer. It uses a small sample of your tumour to see how it might react to different treatments. This helps researchers understand how to better choose treatments in the future, aiming to improve care for patients.
United Kingdom - active not recruitingPHASE1, PHASE2
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.
United Kingdom - active not recruitingPHASE2
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
This study is looking into a new treatment for an aggressive type of breast cancer called triple-negative breast cancer. It combines standard chemotherapy with two newer drugs, Atezolizumab and Ipatasertib, to see if this mix can fight the cancer better before surgery.
United Kingdom - authorisedPhase I and Phase II (Integrated)- First administration to humans
CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III
This study is testing a new cell-based treatment for breast cancer that doesn't respond to usual hormone therapies or targeted drugs (called triple-negative breast cancer). It's an early-stage trial trying to find out if the treatment is safe and if it works for patients with stages II and III of this type of cancer.
Slovenia